Predictive Significance of Systemic Immune-Inflammation Index in Patients with Breast Cancer: A Retrospective Cohort Study

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451. doi:10.3322/caac.21583
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025
   PubMed Web of Science ®Google Scholar
• Yoon CI, Park S, Cha YJ, et al. Associations between absolute neutrophil count and lymphocyte-predominant breast cancer. Breast. 2020;50:141–148. doi:10.1016/j.breast.2019.09.013
   PubMed Web of Science ®Google Scholar
• Romero-Cordoba S, Meneghini E, Sant M, et al. Decoding immune heterogeneity of triple negative breast cancer and Its association with systemic inflammation. Cancers. 2019;11(7):911. doi:10.3390/cancers11070911
   PubMed Web of Science ®Google Scholar
• Mazaki J, Katsumata K, Kasahara K, et al. Neutrophil-to-lymphocyte ratio is a prognostic factor for colon cancer: a propensity score analysis. BMC Cancer. 2020;20(1):922. doi:10.1186/s12885-020-07429-5
   PubMed Web of Science ®Google Scholar
• Wang G, Tan Y, Jiang Y, et al. Prognostic model of D2 radical gastrectomy combined with neoadjuvant chemotherapy for gastric cancer. Risk Manag Healthc Policy. 2023;16:1259–1271. doi:10.2147/RMHP.S413052
   PubMed Web of Science ®Google Scholar
• Mandaliya H, Jones M, Oldmeadow C, Nordman II. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res. 2019;8(6):886–894. doi:10.21037/tlcr.2019.11.16
   PubMed Web of Science ®Google Scholar
• Prodromidou A, Andreakos P, Kazakos C, et al. The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer. Inflamm Res. 2017;66(6):467–475. doi:10.1007/s00011-017-1026-6
   PubMed Web of Science ®Google Scholar
• Liu P, Chen S, Gao X, et al. Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer. Front Immunol. 2022;13:1032907. doi:10.3389/fimmu.2022.1032907
   PubMed Web of Science ®Google Scholar
• Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19(1):2. doi:10.1186/s13058-016-0794-1
   PubMed Web of Science ®Google Scholar
• Guo W, Lu X, Liu Q, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135–4148. doi:10.1002/cam4.2281
   PubMed Web of Science ®Google Scholar
• Jiang C, Lu Y, Zhang S, Huang Y. Systemic immune-inflammation index is superior to neutrophil to lymphocyte ratio in prognostic assessment of breast cancer patients undergoing neoadjuvant chemotherapy. Biomed Res Int. 2020;2020:7961568. doi:10.1155/2020/7961568
   PubMed Web of Science ®Google Scholar
• Xu T, Zhang SM, Wu HM, et al. Prognostic significance of prognostic nutritional index and systemic immune-inflammation index in patients after curative breast cancer resection: a retrospective cohort study. BMC Cancer. 2022;22(1):1128. doi:10.1186/s12885-022-10218-x
   PubMed Web of Science ®Google Scholar
• Peng Y, Chen R, Qu F, et al. Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients. Cancer Biol Ther. 2020;21(2):189–196. doi:10.1080/15384047.2019.1680057
   PubMed Web of Science ®Google Scholar
• Muñoz-Montaño W, Cabrera-Galeana P, Alvarado-Miranda A, et al. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in different phenotypes of locally advanced breast cancer During neoadjuvant systemic treatment. Clin Breast Cancer. 2020;20(4):307–316.e1. doi:10.1016/j.clbc.2019.12.011
   PubMed Web of Science ®Google Scholar
• Graziano V, Grassadonia A, Iezzi L, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 2019;44:33–38. doi:10.1016/j.breast.2018.12.014
   PubMed Web of Science ®Google Scholar
• Qian Y, Tao J, Li X, et al. Peripheral inflammation/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy. Onco Targets Ther. 2018;11:1423–1432. doi:10.2147/OTT.S148496
   PubMed Web of Science ®Google Scholar
• Bhikram T, Sandor P. Neutrophil-lymphocyte ratios as inflammatory biomarkers in psychiatric patients. Brain Behav Immun. 2022;105:237–246. doi:10.1016/j.bbi.2022.07.006
   PubMed Web of Science ®Google Scholar
• Wang Y, Peng C, Cheng Z, et al. The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: a systematic review and meta-analysis. Int J Surg. 2018;55:73–80. doi:10.1016/j.ijsu.2018.05.022
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. Cancer Cell Int. 2020;20(1):224. doi:10.1186/s12935-020-01308-6
   PubMed Web of Science ®Google Scholar
• Azab B, Shah N, Radbel J, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013;30(1):432. doi:10.1007/s12032-012-0432-4
   PubMed Web of Science ®Google Scholar
• Zhu J, Jiao D, Zhao Y, et al. Development of a predictive model utilizing the neutrophil to lymphocyte ratio to predict neoadjuvant chemotherapy efficacy in early breast cancer patients. Sci Rep. 2021;11(1):1350. doi:10.1038/s41598-020-80037-2
   PubMed Web of Science ®Google Scholar
• Ulas A, Avci N, Kos T, et al. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab? J buon. 2015;20(3):714–722.
   PubMed Web of Science ®Google Scholar
• Pistelli M, De Lisa M, Ballatore Z, et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer. 2015;15(1):195. doi:10.1186/s12885-015-1204-2
   PubMedGoogle Scholar
• Corbeau I, Jacot W, Guiu S. Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic review. Cancers. 2020;12(4):958. doi:10.3390/cancers12040958
   PubMed Web of Science ®Google Scholar
• Iwase T, Sangai T, Sakakibara M, et al. An increased neutrophil-to-lymphocyte ratio predicts poorer survival following recurrence for patients with breast cancer. Mol Clin Oncol. 2017;6(2):266–270. doi:10.3892/mco.2016.1101
   PubMedGoogle Scholar
• Che YQ, Zhang Y, Wang D, et al. Baseline lymphopenia: a predictor of poor outcomes in HER2 positive metastatic breast cancer treated with trastuzumab. Drug Des Devel Ther. 2019;13:3727–3734. doi:10.2147/DDDT.S212610
   PubMed Web of Science ®Google Scholar
• Watanabe J, Saito M, Horimoto Y, Nakamoto S. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience. Breast Cancer Res Treat. 2020;181(1):211–220. doi:10.1007/s10549-020-05626-1
   PubMed Web of Science ®Google Scholar
• Lips EH, Mulder L, de Ronde JJ, et al. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat. 2013;140(1):63–71. doi:10.1007/s10549-013-2620-0
   PubMed Web of Science ®Google Scholar
• Nagao T, Kinoshita T, Hojo T, et al. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast. 2012;21(3):289–295. doi:10.1016/j.breast.2011.12.011
   PubMed Web of Science ®Google Scholar
• Litton JK, Gonzalez-Angulo AM, Warneke CL, et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol. 2008;26(25):4072–4077. doi:10.1200/JCO.2007.14.4527
   PubMed Web of Science ®Google Scholar
• Eren T, Karacin C, Ucar G, et al. Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients. Medicine (Baltimore). 2020;99(22):e20346. doi:10.1097/MD.0000000000020346
   PubMed Web of Science ®Google Scholar
• Chen X, He C, Han D, et al. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. Future Oncol. 2017;13(9):843–857. doi:10.2217/fon-2016-0420
   PubMed Web of Science ®Google Scholar
• Bae SJ, Cha YJ, Yoon C, et al. Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy. Sci Rep. 2020;10(1):13078. doi:10.1038/s41598-020-69965-1
   PubMed Web of Science ®Google Scholar
• Pathak M, Dwivedi SN, Deo SVS, et al. Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol. Syst Rev. 2018;7(1):89. doi:10.1186/s13643-018-0754-1
   PubMedGoogle Scholar
• Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, Phase 2 trial. Lancet Oncol. 2012;13(1):25–32. doi:10.1016/S1470-2045(11)70336-9
   PubMed Web of Science ®Google Scholar
• Yao M, Liu Y, Jin H, et al. Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Onco Targets Ther. 2014;7:1743–1752. doi:10.2147/OTT.S69657
   PubMed Web of Science ®Google Scholar
• Liu C, Huang Z, Wang Q, et al. Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone-receptor-negative breast cancer. Onco Targets Ther. 2016;9:4653–4660. doi:10.2147/OTT.S106017
   PubMed Web of Science ®Google Scholar
• Xu Y, Ju L, Tong J, Zhou C, Yang J. Supervised machine learning predictive analytics for triple-negative breast cancer death outcomes. Onco Targets Ther. 2019;12:9059–9067. doi:10.2147/OTT.S223603
   PubMed Web of Science ®Google Scholar
• Polley MC, Leon-Ferre RA, Leung S, et al. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. Breast Cancer Res Treat. 2021;185:557–66.
   PubMed Web of Science ®Google Scholar
• Ballinger TJ, Jiang G, Kassem N, Radovich M, Schneider BP. Impact of body mass index on presence of ctDNA and disease recurrence after neoadjuvant chemotherapy for triple-negative breast cancer: analysis from BRE12-158. Clin Cancer Res. 2021;27(4):1195–1199. doi:10.1158/1078-0432.CCR-20-3341
   PubMed Web of Science ®Google Scholar
• Liu J, Ma F, Sun B, et al. Predictive value of lymphocyte-related blood parameters at the time point of lymphocyte Nadir during radiotherapy in breast cancer. Onco Targets Ther. 2020;13:151–161. doi:10.2147/OTT.S233244
   PubMed Web of Science ®Google Scholar
• Miké V, Currie VE, Gee TS. Fatal neutropenia associated with long-term tamoxifen therapy. Lancet. 1994;344(8921):541–542. doi:10.1016/S0140-6736(94)91929-1
   PubMed Web of Science ®Google Scholar
• Takada K, Kashiwagi S, Asano Y, et al. Clinical evaluation of dynamic monitoring of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in primary endocrine therapy for advanced breast cancer. Anticancer Res. 2019;39(10):5581–5588. doi:10.21873/anticanres.13752
   PubMed Web of Science ®Google Scholar
• Rotstein S, Blomgren H, Petrini B, Wasserman J, Baral E. Long term effects on the immune system following local radiation therapy for breast cancer. I. cellular composition of the peripheral blood lymphocyte population. Int J Radiat Oncol Biol Phys. 1985;11(5):921–925. doi:10.1016/0360-3016(85)90114-2
   PubMed Web of Science ®Google Scholar
• Jiang L, Fang J, Ding J. High systemic immune-inflammation index predicts poor survival in patients with human epidermal growth Factor receptor-2 positive breast cancer receiving adjuvant trastuzumab. Cancer Manag Res. 2020;12:475–484. doi:10.2147/CMAR.S231444
   PubMed Web of Science ®Google Scholar
• Iimori N, Kashiwagi S, Asano Y, et al. Clinical significance of the neutrophil-to-lymphocyte ratio in endocrine therapy for stage IV breast cancer. In Vivo (Brooklyn). 2018;32(3):669–675. doi:10.21873/invivo.11292
   Web of Science ®Google Scholar
• Miyagawa Y, Araki K, Bun A, et al. Significant association between low baseline neutrophil-to-lymphocyte ratio and improved progression-free survival of patients with locally advanced or metastatic breast cancer treated with eribulin but not with nab-paclitaxel. Clin Breast Cancer. 2018;18(5):400–409. doi:10.1016/j.clbc.2018.03.002
   PubMed Web of Science ®Google Scholar
• Schettini F, Sobhani N, Ianza A, et al. Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. Breast Cancer Res Treat. 2020;184(2):421–431. doi:10.1007/s10549-020-05856-3
   PubMed Web of Science ®Google Scholar
• Ibrahim A, Serkan YF, Tuba A, Erol B, Lütfi P. Can neutrophil to lymphocyte ratio be a predictor tool for the non-sentinel lymph node metastasis in breast cancer? Chirurgia (Bucur). 2019;114(1):83–88. doi:10.21614/chirurgia.114.1.83
   PubMed Web of Science ®Google Scholar
• Fang Q, Tong YW, Wang G, et al. Neutrophil-to-lymphocyte ratio, obesity, and breast cancer risk in Chinese population. Medicine (Baltimore). 2018;97(30):e11692. doi:10.1097/MD.0000000000011692
   PubMed Web of Science ®Google Scholar
• Chen L, Kong X, Yan C, Fang Y, Wang J. The research progress on the prognostic value of the common hematological parameters in peripheral venous blood in breast cancer. Onco Targets Ther. 2020;13:1397–1412. doi:10.2147/OTT.S227171
   PubMed Web of Science ®Google Scholar
• Pivatto Júnior F, Santos ÂBS, Englert EF, et al. Monocyte-to-lymphocyte ratio as predictor of cancer therapy-related cardiotoxicity in patients with breast cancer: a pilot cohort study. Breast Cancer Res Treat. 2023;200(3):355–362. doi:10.1007/s10549-023-06979-z
   PubMed Web of Science ®Google Scholar
• Xuan Q, Yang Y, Ji H, et al. Combination of the preoperative albumin to globulin ratio and neutrophil to lymphocyte ratio as a novel prognostic factor in patients with triple negative breast cancer. Cancer Manag Res. 2019;11:5125–5131. doi:10.2147/CMAR.S195324
   PubMed Web of Science ®Google Scholar
• Sata A, Fukui R, Miyagawa Y, et al. C-reactive protein and absolute lymphocyte count can predict overall survival of patients treated with eribulin. Anticancer Res. 2020;40(7):4147–4156. doi:10.21873/anticanres.14414
   PubMed Web of Science ®Google Scholar
• Oba T, Maeno K, Ono M, et al. Prognostic nutritional index is superior to neutrophil-to-lymphocyte ratio as a prognostic marker in metastatic breast cancer patients treated with eribulin. Anticancer Res. 2021;41(1):445–452. doi:10.21873/anticanres.14794
   PubMed Web of Science ®Google Scholar